BioAroundWorld 2022 Sept Event
Review
On September 20th, 2022, MSQ Ventures successfully co-hosted BioAroundWorld Global Cross-Border BioPharma together with BioAroundWorld. This event focuses on cross-border transactions in the healthcare sector between China and the US and biopharma industry technology and knowledge sharing. This time we brought a panel discussion and 5 knowledge-sharing presentations on this event. It attracted many corporate executives, R&D leaders and investors from outstanding healthcare companies and top venture capital institutions in China and the US.
Tony Chen, Partner, Jones Day, Echo Hindle-Yang, President & CEO, MSQ Ventures and Marc Estigarribia, Managing Director, MSQ Ventures gave an opening speech for BioAroundWorld 2022 Sept Event"Cross-Border Healthcare Innovation & Partnership ” . Echo, Tony and Marc shared their insight and expertise on recent happening deal transactions, the market trend changes, and how global captital market affects the fund raising for biopharma companies.
On the panel discussion part, Echo Hindle-Yang moderate the ImaginAB & DC Pharma Successful Case Study, Ian Wilson, Chief Executive Officer, ImaginAb, and Doug Chong, Head of BD Division, DC Pharm as panelists joining panel discussion and sharing their successful cooperation experience on the event. The collaboration between ImaginAb and DC Pharma accelerate the clinical development and commercialization of innovative therapies and meet the unmet clinical needs in China. Dongcheng’s extensive experience in molecular imaging, combined with its technical experience and execution infrastructure make it an ideal development and commercial partner for ImaginAb in China.
Echo is the CEO from MSQ Ventures, which is a NY-based cross-border advisory firm that bridges the healthcare industries globally by offering deep knowledge, strong network, and local insights into the China market. Echo has 20 years of experience in cross-border transactions for fortune global companies, such as IBM, J&J and Lenovo. She has been advising hundreds of western pharmaceutical and medical devices companies on advancing their success in China. Echo holds and MBA from Duke University and is serving on Duke NY Board.
Ian Wilson, CEO of ImaginAb, With over 25 years of experience in development of in vivo medical diagnostics and imaging medical devices. His former role as the CEO and CTO of Edinburgh Molecular Imaging Ltd saw him leading the development of novel optical imaging agents to improve cancer detection, surgery and lung disease. Prior to that, he held several roles at GE Healthcare between 1996 and 2013, with responsibility for management of GE Healthcare’s Molecular Imaging Agent Portfolio. He also had responsibility for supporting efficacy and regulatory studies required for the approval of new imaging agents. At Xstrahl Ltd, as CTO &COO, he was responsible for the oversight of the Radiotherapy commercial operation and manufacture oversight, including new product development.
Doug Chong is the Head of BD Division from DC Pharm. Doug has over 24 years in field of nuclear medicine industry and over 6 yrs of experience in pre-IND, phase III trial and tech transfer in China. Doug has extensive experience in business planning & project management in NM camera, cyclotron, proton therapy and BNCT in China. He holds a BSc in biochemistry, and an EMBA.
Interview highlights include:
Great opportunity and potential of China oncology market
The scope of this collaboration and the strategy to determine the right assets to develop in China
The choice of partner – why DongCheng, and how will DongCheng’s infrastructure advance CD8's commercialization in China.
The key challenges behind this cross-border collaboration.
Please find the detail panel dicusssion for ImaginAb & DC Pharma Successful Case Study below
Finally, we are honored to have Jack Zhang, Senior Strategy Manager, CGT, Lonza , Christopher U Missling, PhD, President & CEO, Anavex Life Sciences, Yi-Chun Maria Chen, VP of Business Development, BRIM Biotechnology, Avery Wen, BD Associate Director, Zhiyi Biotech and Jianqiang Li , PhD, Founder and CSO, Senlang Biotech to be our guest speakers at Knowledge Sharing section. We learned more new drug, techonology and market insights through thier presentation.
Knowledge Sharing
Overall CGT Market Trend And Challenge In CMC
Speaker: Jack Zhang, Senior Strategy Manager, CGT, LonzaInsights For A New Solution For Neurodegenerative Diseases And What Is More
Speaker: Christopher U Missling, PhD, President & CEO, Anavex Life Sciences
PEDF-derived Short Peptide Technology Platform Boosted Drug Development
Speaker: Yi-Chun Maria Chen, VP of Business Development, BRIM BiotechnologyZhiyi Biotech Novel LBPs Development
Speaker: Avery Wen, BD Associate Director, Zhiyi BiotechSenlang Biotech-An All-in-One CAR-T Therapy Platform
Speaker: Jianqiang Li , PhD, Founder and CSO, Senlang Biotech
Please watch the detail knowledge sharing in the video:
The market changes in the biopharma and health industry have also come to an urgent situation. As market economy and needs continue to change, the healthcare industry must re-examine its business model and take more decisive reforms to better meet market needs. In this global biopharma event, we gathered to have more exchanges, bringing some industry trends and professional knowledge. Let’s looking forward to our next time event!
Any inquiries, please contact us at event@msqventures.com